Angiogenesis in male breast cancer

被引：0
作者：
Frangou E.M. [1 ]
Lawson J. [2 ]
Kanthan R. [1 ]
机构：
[1] Department of Pathology, University of Saskatchewan, Royal University Hospital, Saskatoon, Sask.
[2] Institute of Agricultural Rural Environmental Health, University of Saskatchewan, Royal University Hospital, Saskatoon, Sask.
来源：
World Journal of Surgical Oncology | / 3卷 / 1期
关键词：
Vascular Endothelial Growth Factor; Invasive Ductal Carcinoma; Male Breast; Vascular Endothelial Growth Factor mRNA; Male Breast Cancer;
D O I：
10.1186/1477-7819-3-16
中图分类号：
学科分类号：
摘要：
Background: Male breast cancer is a rare but aggressive and devastating disease. This disease presents at a later stage and in a more advanced fashion than its female counterpart. The immunophenotype also appears to be distinct when compared to female breast cancer. Angiogenesis plays a permissive role in the development of a solid tumor and provides an avenue for nutrient exchange and waste removal. Recent scrutiny of angiogenesis in female breast cancer has shown it to be of significant prognostic value. It was hypothesized that this holds true in invasive ductal carcinoma of the male breast. In the context of male breast cancer, we investigated the relationship of survival and other clinico-pathological variables to the microvascular density of the tumor tissue. Methods: Seventy-five cases of primary male breast cancer were identified using the records of the Saskatchewan Cancer Agency over a period of 26 years. Forty-seven cases of invasive ductal carcinoma of the male breast had formalin-fixed paraffin-embedded tissue blocks that were suitable for this study. All cases were reviewed. Immunohistochemical staining was performed for the angiogenic markers (cluster designations 31 (CD31), 34 (CD34) and 105 (CD105), von Willebrand factor (VWF), and vascular endothelial growth factor (VEGF)). Microvascular density (MVD) was determined using average, centre, and highest microvessel counts (AMC, CMC, and HMC, respectively). Statistical analyses compared differences in the distribution of survival times and times to relapse between levels of MVD, tumor size, node status and age at diagnosis. In addition, MVD values were compared within each marker, between each marker, and were also compared to clinico-pathological data. Results: Advanced age and tumor size were related to shorter survival times. There were no statistically significant differences in distributions of survival times and times to relapse between levels of MVD variables. There was no significant difference in MVD between levels of the different clinico-pathological variables. MVD was strongly and significantly correlated between AMC, CMC and HMC for CD31, CD34, and CD105 (p < 0.01) and remained moderate to weak for VWF and VEGF. Conclusion: Microvascular density does not appear to be an independent prognostic factor in male breast cancer. However, the likelihood of death for men with breast cancer is increased in the presence of increased age at diagnosis and advanced tumor size. This is perhaps linked to inherent tumor vasculature, which is strongly related throughout a tumor section. © 2005 Frangou et al; licensee BioMed Central Ltd.
引用
收藏
页数：14
相关论文
共 95 条
[1]  
Giordano S.H., Cohen D.S., Buzdar A.U., Perkins G., Hortobagyi G.N., Breast carcinoma in men: A population-based study, Cancer, 101, pp. 51-57, (2004)
[2]  
Donegan W.L., Redlich P.N., Lang P.J., Gall M.T., Carcinoma of the breast in males: A multiinstitutional survey, Cancer, 83, pp. 498-509, (1998)
[3]  
Gough D.B., Donohue J.H., Evans M.M., Pernicone P.J., Wold L.E., Naessens J.M., O'Brien P.C., A 50-year experience of male breast cancer: Is outcome changing?, Surg. Oncol., 2, pp. 325-333, (1993)
[4]  
Hittmair A.P., Lininger R.A., Tavassoli F.A., Ductal carcinoma in situ (DCIS) in the male breast: A morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma - A preliminary report, Cancer, 83, pp. 2139-2149, (1998)
[5]  
Camus M.G., Joshi M.G., Mackarem G., Lee A.K., Rossi R.L., Munson J.L., Buyske J., Barbarisi L.J., Sanders L.E., Hughes K.S., Ductal carcinoma in situ of the male breast, Cancer, 74, pp. 1289-1293, (1994)
[6]  
Muir D., Kanthan R., Kanthan S.C., Male versus female breast cancers. A population-based comparative immunohistochemical analysis, Arch. Pathol. Lab. Med., 127, pp. 36-41, (2003)
[7]  
Weber-Chappuis K., Bieri-Burger S., Hurlimann J., Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas, Eur. J. Cancer, 32 A, pp. 1686-1692, (1996)
[8]  
Borgen P.I., Senie R.T., McKinnon W.M., Rosen P.P., Carcinoma of the male breast: Analysis of prognosis compared with matched female patients, Ann. Surg. Oncol., 4, pp. 385-388, (1997)
[9]  
Cutuli B., Lacroze M., Dilhuydy J.M., Velten M., De Lafontan B., Marchal C., Resbeut M., Graic Y., Campana F., Moncho-Bernier V., Et al., Male breast cancer: Results of the treatments and prognostic factors in 397 cases, Eur. J. Cancer, 31 A, pp. 1960-1964, (1995)
[10]  
Joshi M.G., Lee A.K., Loda M., Camus M.G., Pedersen C., Heatley G.J., Hughes K.S., Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome, Cancer, 77, pp. 490-498, (1996)
12345678910